Marcuse F, Hochstenbag M, Hoeijmakers JGJ, et al. - In this retrospective analysis, researchers investigated the prevalence as well as long-term results of subclinical myasthenia gravis (MG) in patients with thymomas. Participants were patients who had a robotic-assisted thoracoscopic surgery at the Maastricht University Medical Center+ (MUMC+) between April 2004 and December 2018. Findings revealed a 10.8% prevalence of subclinical MG in thymomas. Anti-AChR-antibodies seemed to be present in one in four patients who had no neurological symptoms prior to thymectomy, and the development of clinical MG was seen within 6 years post-thymectomy in 91% of these patients. In all suspected thymomas, serum analysis for anti-AChR-antibodies is advised prior to performing a thymectomy.